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patient compliance. Sustained release (SR) formulation that 
would maintain plasma levels of drug for 8–12 h might be 
sufficient for once daily dosing for metformin. SR products 
are needed for metformin to prolong its duration of action 
and to improve patient compliance.[3]
Sustained or controlled drug delivery occurs while 
embedded within a polymer that may be natural or 
semisynthetic or synthetic in nature. The polymer is 
judiciously combined with the drug or other active 
ingredients in such a way that the active agent is released 
from the material in a predetermined fashion and released 
the drug at a constant rate for a desired time period.[4]
Solid dispersion (SD), in which compounds are dispersed 
into water-soluble carriers, has been generally used to 
improve the dissolution properties and the bioavailability 
of drugs that are poorly soluble in water.[5] SD has also 
been applied for the controlled release of drugs. Previous 
INTRODUCTION 
Metformin hydrochloride (MET) is an oral antihyperglycemic 
agent, highly water-soluble, whose low bioavailability and 
short and variable biological half-life (1.5–4.5 h) needs 
frequent administrations to maintain effective plasma 
concentrations.[1] Unlike other biguanide drugs, metformin 
does not induce lactic acidosis. However, current 
metformin therapy is suboptimal as it is associated with 
a high incidence of gastrointestinal side effects, seen in 
about 30% of the patients, thus making the development 
of sustained-release forms desirable.[2] An obstacle to 
more successful use of metformin therapy is the high 
incidence of concomitant gastrointestinal symptoms, 
such as abdominal discomfort, nausea and diarrhea, which 
especially occur during the initial weeks of treatment. 
Side effects and the need for administration two or three 
times per day when larger doses are required can decrease 
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reports have shown that by using SDs containing a 
polymer blend, such as hydroxypropylcellulose (HPMC) 
and ethylcellulose, it is possible to precisely control the 
rate of release of an extremely water-soluble drug, such 
as oxprenolol hydrochloride.[6] SDs of methylcellulose and 
carboxyvinylpolymer for phenacetin[7] and Eudragit for 
diclofenac sodium.[8] These studies have shown that there 
is a linear relationship between the rate of release of the 
water-insoluble drug and its interaction with the polymer.
A wide array of polymers has been employed as drug-
retarding agents, each of which presents a different 
approach to the matrix concept. Polymers that primarily 
form insoluble or skeleton matrices are considered as the 
first category of retarding materials. The second class 
represents hydrophobic and water-insoluble materials, 
which are potentially erodible, and the third group exhibits 
hydrophilic properties.[9]
There are three primary mechanisms by which active 
agents can be released from a delivery system: diffusion, 
degradation and swelling followed by diffusion. The release 
of drug from the matrix depends on the nature of the 
polymer. Methocel K100M is a hydrophilic polymer that 
becomes hydrated, swollen and facilitates diffusion of the 
drug.[10] In the present study, an attempt has been made 
to formulate metformin as SR SD with the addition of 
release-retarding polymer methocel K100M in different 
ratios. The effects of polymer loading on drug release were 
recorded and the release kinetics was evaluated.
MATERIALS AND METHODS
MET was kindly supplied by Indoco Remedies (Goa, India) 
and hydroxypropylmethylcellulose (Methocel K100M) was 
obtained from Colorcon Asia Pvt. Ltd. (Mumbai, India). 
All other chemicals and solvents were of reagent grade.
Preparation of physical mixtures
Physical mixtures of MET and methocel in powder form 
were mixed in mortar and passed through sieve no. 60. The 
physical mixtures were prepared in the following ratios: 
MET:HPMC in the ratios of 1:1, 1:2, 1:3, 1:4 and 1:5.[11]
SDs prepared by the solvent evaporation method
SDs were prepared by dissolving accurately weighed 
amounts of methocel and MET in ethanol.[12] After 
complete dissolution, the solvent was left to evaporate 
in open air for 2 days. Subsequently, the solid mass was 
ground and passed through sieve no 60. The sieved ground 
powders were stored at 25oC in a desiccator in a screw-
capped glass vial until use.
SDs prepared by the cogrinding method
MET was triturated with a minimum quantity of ethanol 
in a glass mortar until it dissolved.[13] The carrier was then 
added and the suspension was triturated rapidly at room 
temperature until the solvent evaporated and passed 
through sieve no 60.
Evaluation and characterization of SD
Drug content and percent yield
Physical mixtures and SDs equivalent to 10 mg of MET 
prepared were weighed accurately and dissolved in a 100 
ml of distilled water.[14] The stock solutions were filtered 
through a membrane filter (0.45 mm). The solutions were 
then diluted suitably in distilled water. The drug content 
was analyzed at 232 nm using a UV spectrophotometer 
(Varian Cary 100, Australia). Each sample was analyzed in 
triplicate. The percentage yield of each formulation was 
also calculated.
Spectroscopic studies
Drug–polymer interactions between MET and HPMC 
was studied by the spectral shift method. Ten milligrams 
of each drug, carrier and SDs were dissolved in 100 ml 
double-distilled water (DDW), filtered using Whatman 
filter paper no. 41 and degassed by sonication for 30 min.  [15] 
After appropriate dilutions using DDW, the solutions were 
scanned at 232 nm with a UV spectrophotometer (Varian 
Cary 100).
Dissolution study
The dissolution studies were performed using a US 
Pharmacopeia 24 type II dissolution test apparatus 
(Electrolab TDT-08L, Mumbai, India). The samples 
equivalent to 10 mg MET were placed in a dissolution 
vessel containing 900 ml of DDW maintained at 37 ± 
0.5oC and stirred at 100 rpm. Five-milliliter samples were 
collected periodically and replaced with a fresh dissolution 
medium. After filtration through Whatman filter paper 
no. 41, the concentration of metformin was determined 
spectrophotometrically at 232 nm.[16] Data were analyzed 
using PCP Disso software (version 3.0).
Dissolution efficiency (DE)
The DE of various SDs was calculated. DE is used 
as the criterion for comparing the effect of polymer 
concentration on the release rate. DE is defined as the area 
under the dissolution curve up to the time “t,” expressed 
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as percentage of the area of rectangle described by 100% 
dissolution in the same time as in equation 1.[17]
  0 ∫ T Y x dt
DE=   --------------- x 100 %  ---Eq. 1
   
Y100 X T
where Y is the percent drug release as the function of 
time, t, T is the total time of drug release and Y100 is 100% 
drug release.
Release experiments
In order to gain insight into the drug release mechanism 
from the SD, release data of selected formulations were 
examined according to the zero-order, first-order and 
Higuchi’s square root of time mathematical models, 
Hixson and Crowell powder dissolution method and 
Korsmeyer and Peppas model and the release exponent 
n was calculated.[18] The equations for the said models are 
given in Table  1. All the dissolution profiles were subjected 
to model fitting using PCP Disso software (version 3.0).
A n-value 0.5 is considered consistent with a diffusion-
controlled release, whereas a value of 1.0 indicates a 
zero-order release behavior, and intermediate values 
(0.5   >   n   >   1.0) are defined as anomalous non-Fickian 
transport mechanism.[19]
Similarity factor (f2) analysis
The in vitro release profile of the marketed MET SR 
tablets, (Glumet XR®, Cipla, Solan-Himachal Pradesh, 
India) was performed under similar conditions as used for 
in vitro release testing of the test product for the release 
of metformin. The similarity factor between the two 
formulations was determined using the data obtained from 
the drug-release studies.[20] The data were analyzed by the 
formula shown in equation 2.
f2 = 50 log {[ 1+ (1/N) Σ (Ri – Ti)2 ] −0.5 X 100 }    
  ---Eq. 2
where N = number of time points, Ri and Ti = dissolution 
of reference and test products at time i. If f2 is greater 
than 50, it is considered that the two products share similar 
drug release behaviors.[21]
Diffuse reflectance infrared Fourier transform spectroscopy (DRIFTS)
The DRIFTS spectra of pure MET, physical mixtures 
and SDs were obtained after appropriate background 
subtraction using an FTIR spectrometer (FTIR-640 IR, 
Varian, Australia). About 2–3 mg of the sample was mixed 
with dry potassium bromide and the sample was scanned 
from 4,000 to 400 cm-1.[22]
Differential scanning calorimetry (DSC)
The calorimeter used DSC 823e (Mettler Toledo, 
Switzerland) was equipped with an intracooler, a 
refrigerated cooling system. Indium standard was used to 
calibrate the DSC temperature and enthalpy scale. Nitrogen 
was used to purge gas through the DSC cell at a flow 
rate of 50 ml/min and 100 ml/min through the cooling 
unit.  [23] The samples (5–10 mg were hermetically sealed in 
an aluminum pan and heating was carried out at 5oC/min.
Solid dispersion of metformin hydrochloride
Table 1: Kinetics of optimized solid dispersions of metformin hydrochloride
Model Equation SM4 SM5 CM5
R2 k R2 k R2 k
Zero order F = k X t 
(where F is 
the fraction of 
drug release, k 
is the release 
constant and t 
is the time)
0.7801 11.7440 0.8382 11.2127 0.5922 11.3547
First order ln F = k X t 
(where F is 
the fraction of 
drug release, k 
is the release 
constant and t 
is the time)
0.9932 -0.2868 0.9948 -0.2488 0.9611 -0.2416
Higuchi matrix F = k√ t 0.9928 31.9689 0.9972 30.3726 0.9643 31.2308
Hixson and Crowell 
powder dissolution 
method
F = 100  
(1-(1-kt)3)
0.9776 -0.0673 0.9809 -0.0611 0.8901 -0.0606
Korsmeyer and Peppas 
modela
F = ktn 0.9978 37.3839 0.9967 32.6910 0.9937 42.2406
a, n (diffusional coefficient) for SM4 n = 0.4512, for SM5 n= 0.4597, for CM5 n=0.3369124   J Young Pharm Vol 2 / No 2
X-ray powder diffractometry (XRPD)
The powder X-ray diffraction patterns of powdered 
samples were recorded using a Philips PW-1729 X-ray 
diffractometer (Philips House, Cambridge-UK). Samples 
were irradiated with monochromatized CuKα radiation and 
a graphite monochromator. The samples were analyzed in 
the 5–50◦ 2θ range at a scan rate of 0.05◦ per second.[24]
Stability studies
Stability studies were conducted on MET SDs along with 
physical mixtures to assess their stability with respect to 
their physical appearance, drug content, FTIR spectroscopy 
and drug-release characteristics after storing them at 40oC 
and relative humidity (RH) 75% for 1 month and at room 
temperature for 6 months.[25]
RESULTS
Drug contents and percent yield
Table 2 summarizes the actual composition and percentage 
yield along with abbreviations used for the SDs. Because 
of difficulty in collecting all the solid material from the 
flask after ethanol evaporation, the production yields 
of SDs from solvent evaporation ranged between 
87.33 ± 0.49 and 94.67 ± 0.55%. However, satisfactory 
reproducibility of results when repeating the preparation 
was observed.
The production yields of SDs from cogrinding ranged 
between 93.50 ± 0.39 and 99.20 ± 0.52%. The amount of 
drugs determined in each SD was between 94.56 ± 0.36 
and 98.72 ± 1.11% for solvent evaporation and 95.86 ± 
0.80 and 104.27 ± 0.91% for cogrinding.
Spectroscopic studies
The UV spectra of MET and SDs were studied. The 
observed absorbance in case of SD was reduced than that of 
the pure drug. There is no shift in the λmax of metformin in 
the presence of methocel. The induced change in absorbance 
is attributed, primarily, to the weak hydrogen bonding.
Dissolution study
The dissolution profiles of MET SDs along with physical 
mixture in DDW are shown in Figures 1 and 2 for solvent 
evaporation and cogrinding, respectively. MET completely 
dissolved within a few minutes, reflecting its high aqueous 
solubility. The dissolution from the physical mixture 
showed approximately the same behavior of pure MET, 
with only a very slight initial slowing down of the drug 
dissolution rate due to the presence of the hydrophilic 
HPMC, which reduces the drug wettability.
Dissolution efficiency
DE was used to compare the dissolution data, as shown 
in Table 2. DE values are consistent with the dissolution 
data. For example, the DE value for the SDs containing 1:1 
drug:HPMC ratio is 93.86%, whereas this value decreased 
to 67.96 and 63.97% for the SDs containing 1:4 and 1:5 
ratio of HPMC, respectively, for SDs prepared by the 
solvent evaporation method.
The SDs showing the desired release profile were selected as 
optimized batches for further evaluations. The SDs of MET 
with methocel K100M, which were selected as optimized 
batches for further evaluation, were SM4, SM5 and CM5, 
depending on the release profiles as per USP test 2.[26]
Table 2: Abbreviations, percentage drug content, yield and dissolution efficiency for the solid dispersions
Method of preparation Abbreviations % drug contenta % yielda Dissolution efficiency
Physical mixture 1:1 PM1 98.41 ± 0.78 97.50 ± 1.53 -
Physical mixture 1:2 PM2 102.57 ± 1.25 94.93 ± 0.88 -
Physical mixture 1:3 PM3 103.99 ± 0.87 96.46 ± 1.12 -
Physical mixture 1:4 PM4 96.49 ± 0.69 97.44 ± 0.42 -
Physical mixture 1:5 PM5 99.53 ± 1.08 96.79 ± 0.93 -
Solvent evaporation 1:1 SM1 97.22 ± 0.45 94.67 ± 0.55 93.86
Solvent evaporation 1:2 SM2 94.56 ± 0.36 92.90 ± 1.03 91.00
Solvent evaporation 1:3 SM3 97.41 ± 0.22 87.33 ± 0.49 79.70
Solvent evaporation 1:4 SM4 98.72 ± 1.11 87.46 ± 0.77 67.96
Solvent evaporation 1:5 SM5 96.03 ± 0.55 90.0 ± 0.62 63.97
Cogrinding 1:1 CM1 98.27 ± 0.96 99.20 ± 0.52 92.82
Cogrinding 1:2 CM2 100.06 ± 0.75 93.50 ± 0.39 91.81
Cogrinding 1:3 CM3 95.86 ± 0.80 98.0 ± 1.19 88.19
Cogrinding 1:4 CM4 104.27 ± 0.91 95.33 ± 1.07 78.28
Cogrinding 1:5 CM5 97.93 ± 1.02 93.67 ± 0.67 67.59
a, expressed as mean ± (SD) standard deviation, n = 3
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Release experiments
The release data of selected SDs were examined according 
to the zero-order, first-order and Higuchi’s square root of 
time mathematical models, Hixson and Crowell powder 
dissolution method and Korsmeyer and Peppas model 
and the release exponent n was calculated. Table 1 shows 
the data for kinetics of SDs. It can be observed that the 
Higuchi equation was the most suitable mathematical 
model for describing experimental data only for SM5 
containing drug to polymer in a 1:5 ratio, indicating 
that diffusion through the matrix was the main factor 
in controlling the drug release rate from SM5 SDs. This 
was also evidenced by the value of the release exponent 
n (0.4597), which was rather near to the theoretical 
one expected for a Fickian diffusion-controlled release 
mechanism (n = 0.5). Whereas in case of SM4, the 
Korsmeyer-Peppas equation was most suitable with R2 
value of 0.9978 and that of first-order equation was 
0.9932, indicating that the drug-release pattern is followed 
by both the equations.
The in vitro release pattern of the coground CM5 SDs was 
analyzed by fitting the dissolution data into various kinetic 
models. It was observed that the R2 value was higher when 
fitted to Korsmeyer-Peppas equation as compared to zero-
order equation, which indicated Peppas as the best fitting 
kinetic model for CM5.
Similarity factor (f2)
The similarity factor f2 method can be used to compare 
two dissolution profiles. Similarity factor analysis between 
the prepared SDs and the marketed tablet (Glumet XR®, 
Cipla) for the release of MET showed an f2 factor >50; f2 
= 50.38, f2 = 59.01 and f2 = 51.57 for SM4, SM5 and CM5, 
respectively. As shown in Table 3, the f2 factor confirms 
that the release of MET from the prepared SDs was similar 
to that of the marketed tablet.
DRIFTS
The FTIR spectrum of pure MET showed two typical 
Solid dispersion of metformin hydrochloride
Figure 1: Dissolution profile of metformin hydrochloride, physical 
mixture and solid dispersions by the solvent evaporation method
Figure 2: Dissolution profile of metformin hydrochloride, physical 
mixture and solid dispersions by the cogrinding method
Table 3: f2 factor results
Time Average % release f2
Reference SM4 SM5 CM5 SM4 SM5 CM5
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 28.30 38.19 33.83 40.09 57.56 69.75 53.81
2 41.68 48.40 43.54 55.08 57.82 72.75 49.25
3 51.92 57.21 52.22 64.03 58.98 75.56 48.28
4 59.17 67.19 60.77 68.23 57.99 77.01 48.93
5 64.78 74.02 68.80 73.12 56.63 75.24 49.60
6 67.34 80.27 77.03 77.26 53.78 66.46 49.67
7 71.17 84.58 82.29 81.65 51.84 61.46 49.56
8 75.90 89.58 86.72 84.60 50.45 58.90 49.88
9 81.35 92.52 88.22 87.13 50.12 58.79 50.62
10 86.81 95.31 92.63 89.46 50.38 59.01 51.57
Average -- -- -- -- 50.38 59.01 51.57126   J Young Pharm Vol 2 / No 2
bands at 3369 cm-1 and 3294 cm-1 relative to the N–H 
primary stretching vibration and a band at 3155 cm-1 due 
to the N–H secondary stretching, and characteristic bands 
at 1626 cm-1 and 1567 cm-1, assigned to C-N stretching. IR 
spectra of HPMC shows typical bands at 3451 cm-1 due 
to O-H stretching, 1644 cm-1 due to sugar ring and 1064 
cm-1 due to C-O (etheric) stretching. The physical mixture 
spectrum [Figures 3 and 4] can be considered as the sum of 
pure MET and HPMC spectra. The absolute zero changes 
of the peak shift in case of physical mixture observed as 
subtraction of HPMC spectra from PM spectra revealed 
the pure MET spectra.
DSC
The thermal curves of MET and of selected SDs along 
with physical mixture are shown in Figure 5 The thermal 
curve of pure MET [Figure 5a] exhibited an initial flat 
profile followed by a sharp endothermic effect, with a 
Tonset at 229.7oC, a Tpeak at 231.0oC and an associated fusion 
enthalpy of 292.2 J/g, indicative of its anhydrous crystalline 
state. The DSC profile of HPMC [Figure 5b] was typical of 
amorphous substances, showing a large dehydration band 
in the 50o–120oC temperature range. The thermal curve of 
the physical mixture [Figure 5c] was practically the sum of 
those of pure components, showing endothermic effect 
due to polymer dehydration followed by sharp endothermic 
peak at 231oC corresponding to the melting point of the 
drug. The thermograph of SM4 [Figure 5d] and CM5 
[Figure 5e] displayed a slight reduction of fusion enthalpy 
and also endothermic peak, changing the melting point of 
MET to 226oC.
PXRD
Figure 6 shows the powder XRD patterns of pure drug, 
methocel K100M, physical mixture (1:3), SDs prepared 
by solvent evaporation (SM4) and SD prepared by the 
cogrinding method (CM5) with methocel K100M.
In PXRD, sharper diffraction peaks indicate more 
crystalline material. The sharp, intense representative 
peaks of pure MET [Figure 6a], notably at 2θ angles, were 
17o, 22o, 23o, 31o and 45o. This series of sharp and intense 
diffraction peaks indicated the crystalline state of pure 
MET. The diffraction peaks obtained in case of methocel 
[Figure 6b] is not distinct due to the amorphous nature 
of the polymer. The diffraction pattern of the physical 
mixture [Figure 6c] was simply the superimposition of 
those of pure components. In case of SD prepared by the 
solvent evaporation method [Figure 6d] and co-grinding 
method [Figure 6e], the diffraction patterns were much 
similar to that of physical mixture showing all the intense 
peaks except at 45o of MET.
Stability studies
No visible changes in the appearance of the SD were 
observed at the end of the storage period. Drug content 
and dissolution of metformin was almost similar to that at 
time zero during the whole period of investigation. FTIR 
spectroscopy studies for stability were also conducted on 
SDs before and after the storage. FTIR studies concluded 
that there has not been any new bond formation between 
the drug and the carriers, as there has not been any new 
peak in the spectra nor has there been deletion of any 
existing characteristic peak.
DISCUSSION
In vitro release study
Drug release was fast from SM1 and SM2 SDs, with 97.78 
Figure 3: FTIR spectra of metformin hydrochloride, methocel K100M, 
physical mixtures and solid dispersions by the solvent evaporation 
method
Figure 4: FTIR spectra of metformin hydrochloride, methocel K100M, 
physical mixtures and solid dispersions by the cogrinding method
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and 95.02% drug released after 3 h, because it underwent 
erosion before complete swelling could take place. The 
overall drug release is affected by the rate of water uptake 
and the diffusion rate of the drug through the swollen 
gel. High polymer content results in a greater amount of 
gel being formed. This gel increases the diffusional path 
length of the drug. Its viscous nature also affects the 
diffusion coefficient of the drug. As a result, a reduction 
in drug release rate is obtained. SM3 SD showed faster 
dissolution rate in an intermediate time of 2–6 h, which 
did not match with the reference product. On increasing 
the quantity of HPMC in 1:4 and 1:5 ratio of drug, 
prolonged release of the drug was achieved, giving drug 
release of 95.31 and 92.63%, respectively, after 10 h and 
in the desired pattern. SM4 and SM5 SDs shows similar 
drug release pattern suggesting that further increasing the 
polymer ratio above 1:4 does not significantly reduce the 
release rate of MET.
The drug release from SDs by cogrinding after the first 2 h 
were 93.03, 88.13, 80.38, 60.34 and 55.08% for CM1, CM2, 
CM3, CM4 and CM5, respectively. As the ratio of drug 
to polymer increases, there is a significant decrease in the 
drug release from the SDs, reaching 90% of dissolved drug 
after about 3 and 4 h for CM2 and CM3. As the quantity 
of polymer increases further, there is also decrease in the 
amount of drug release from SD, giving an extended release 
up to 10 h for CM4 and CM5. The slow drug-release form 
SD, namely CM4 and CM5, can be attributed to the low 
permeability of the polymer, which posed a significant 
hindrance to fluid penetration and passive drug diffusion. 
Almost 100% drug is released after 8 h in all the SDs 
excluding CM5 SDs. After 8 h, the drug release from CM5 
SDs was found to be 84.60%, showing compliance with 
the desired release profile.
The results indicate that there is reduction in drug release 
as there is increase in the amount of HPMC. However, it 
seems that there is no change in the release pattern as the 
amount of HPMC is increased further. DE values for SDs 
prepared by the cogrinding method were 92.82, 78.28 and 
67.59% for CM1, CM4 and CM5, respectively, suggesting 
that there is reduction in drug release as there is increase 
in HPMC amount in SD.
Kinetic studies
The mechanism of drug release from hydrophilic SD after 
ingestion is complex, but it is based on diffusion of the 
drug through, and erosion of, the outer hydrated polymer 
on the surface of the SD. Typically, when the dispersion is 
exposed to an aqueous solution or gastrointestinal fluids, 
the surface of the dispersion is wetted and the polymer 
hydrates to form a gel layer around the drug. This leads 
to relaxation and swelling of the polymer, which also 
contributes to the mechanism of drug release. The core 
of the dispersion remains essentially dry at this stage. 
In the case of highly soluble drugs like metformin, this 
phenomenon may lead to an initial burst release due to 
the presence of the drug on the surface of the dispersion, 
which is evident by the dissolution data. The gel layer 
grows with time as more water permeates into the core 
of the dispersion, thereby increasing the thickness of the 
gel layer and providing a diffusion barrier to drug release. 
Simultaneously, as the outer layer becomes fully hydrated, 
the polymer chains become completely relaxed and can 
no longer maintain the integrity of the gel layer, thereby 
leading to disentanglement and erosion of the surface of 
the dispersion. Water continues to penetrate toward the 
core of the dispersion, through the gel layer, until it has 
been completely eroded.
Solid dispersion of metformin hydrochloride
Figure 5: Differential scanning calorimetry curves of (a) metformin 
hydrochloride, (b) methocel, (c) physical mixtures, (d) SM4, (e) CM5 SD
Figure 6: X-ray diffraction pattern of (a) metformin hydrochloride, (b) 
methocel, (c) physical mixtures, (d) SM4, (e) CM5 SD128   J Young Pharm Vol 2 / No 2
FTIR
The representative peaks of pure MET were unaltered 
in PM. The FTIR spectra of the solvent evaporation 
[Figure 3] and, even more so, of the cogrinding [Figure 
4] SDs presented appreciable shifts and reduction in 
intensity of the characteristic MET bands at 3369 cm-1 
and 3294 cm-1, which may be due to weak hydrogen 
bonding between the drug and polymer. The weak 
hydrogen bonding in case of solvent evaporation 
was less likely to be stronger than SD by cogrinding. 
The DSC thermographs of SDs revealed that slight 
downward shift in the endothermic peak of MET also 
implicit the interaction of MET with methocel. This may 
be due to the weak hydrogen bonding among NH, NH2 
groups of MET and OH group of the methocel. It also 
suggests the presence of more or less intense solid-state 
interactions between the components.
DSC
Slight reduction of fusion enthalpy and lowering of melting 
temperature of MET observed in the solvent evaporation 
and, particularly, in the cogrinding SD, can be ascribed to 
some drug–polymer interactions occurring during sample 
preparation. Because there is no complete disappearance 
of melting peak corresponding to both SDs, it indicates 
retention of the crystalline nature as a consequence of the 
absence of strong drug–carrier interactions and/or drug 
inclusion complexation.
PXRD
The significant decrease in the representative peak intensity 
height of SD comparatively with the physical mixture and 
pure MET clearly revealed the conversion of the crystalline 
nature of MET to the amorphous form.
Stability studies
Stability studies of the formulation showed that the SD were 
stable, with no significant change in the physicochemical 
characteristics. The improved stability of SD could be due 
to the hydrogen bonding between the drug and HPMC.
CONCLUSION
The proposed strategy of simultaneously exploiting the 
combination of the drug with a hydrophilic polymer 
such as methocel K100M and its SD was effective in 
adequately modulating the drug-release rate. Spectroscopic 
studies reveled the absence of interaction between drug 
and polymer. Release experiments demonstrate that the 
SR effects can be obtained by simply varying the relative 
amounts of the polymer in the dispersion. The actual 
effectiveness of SDs as extended release dosage forms is 
strongly dependent on the preparation technique used for 
obtaining SD. SDs prepared by solvent evaporation using 
methocel K100M were capable of prolonging the release 
of metformin for 10 h at 80% concentration and by the 
cogrinding method at 83% concentration of the polymer. 
The mechanism of drug release was observed to follow 
the Korsemeyer-Peppas model for SM4 and CM5 and the 
Higuchi matrix model for SM5 SDs.
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